Lightnews — Scholar-powered news

Office of Health Economics @ohenews.bsky.social · 2d

Drug shortages are growing, lasting longer, and hitting patients hard. OHE’s submission to Parliament sets out causes, risks, and reforms to strengthen UK supply chains. www.ohe.org/insights/ohe...

Office of Health Economics @ohenews.bsky.social · 9d

To close the sustainability gap, creating a health system that is both low-carbon and resilient to climate impacts must be a strategic priority woven into every NHS decision.

Read more about the path to a greener NHS in this Insight by Nadine Henderson: www.ohe.org/insights/env...

Environmental sustainability in the NHS 10 Year Health Plan: The need for green - OHE

This is the second in a series of blogs about how the proposals in the recently published 10 Year Plan measure up against some of the most pressing health concerns in the UK.

www.ohe.org

1

Office of Health Economics @ohenews.bsky.social · 13d

Pain/discomfort matters most to people with acute leukemia, but cognition, tiredness, and other aspects shape daily life too. Standard tools can miss these. Capturing patient priorities ensures care and policy improve quality of life, not just clinical outcomes. www.ohe.org/publications...

Understanding the preferences of people with acute leukemia for different health outcomes - OHE

When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe the problems they have with different aspects of their health. In this study, we wan...

www.ohe.org

Office of Health Economics @ohenews.bsky.social · 14d

Saudi Arabia is formalising #HTA, adopting value-based pricing, and restructuring #healthcare delivery. What do these changes mean for #marketaccess and #policy in the region? Read our latest insight: www.ohe.org/insights/sau...

Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape - OHE

The next stop in our around the world in HTAs adventure is Saudi Arabia. This blog breaks down how the Kingdom is reshaping access to new health technologies through regulatory reform, a formal HTA fr...

www.ohe.org

2

Office of Health Economics @ohenews.bsky.social · 16d

It is Frontotemporal Dementia Awareness Week. OHE is contributing to the PREDICT-FTD consortium, which aims to advance a biomarker-based diagnosis of frontotemporal dementia. www.ohe.org/insights/the-true-cost-and-burden-of-frontotemporal-dementia-early-insights-into-a-pressing-challenge/

Office of Health Economics @ohenews.bsky.social · 21d

The NHS 10 Year Health Plan puts prevention at the centre. Misaligned incentives, behavioural barriers, and risks of widening inequalities raise the question: can prevention truly move from ambition to action? Find out: www.ohe.org/insights/pre...

1

Office of Health Economics @ohenews.bsky.social · Sep 2

China’s evolving HTA system is transforming access to medicines for 1.4B people. 700+ drugs added to the NRDL since 2017, but there are still challenges like transparency and data gaps. Read the insight:

Office of Health Economics @ohenews.bsky.social · Jul 23

Climate action is health action. Health economics can help shape smarter, fairer decisions – from green #HTA to valuing co-benefits of #climatepolicy. www.ohe.org/insights/cli...

1

Office of Health Economics @ohenews.bsky.social · Jul 21

What is STRIDES? A new #framework to capture the full value of #AMR diagnostics in tackling #antimicrobial resistance. Read more on how #diagnostics can help fight AMR: www.ohe.org/insights/fro...

Office of Health Economics @ohenews.bsky.social · Jun 26

How can we use health economics to inform climate-related policy without needing new frameworks?

📆 8 July 2025
🕛 10:00 BST
📍 Virtual event

Register here: www.ohe.org/events/valui...

#healtheconomics #climatechange #sustainability #publichealth

Office of Health Economics @ohenews.bsky.social · Jun 18

Health reforms in the Middle East are bold, fast, and values-driven. #HTA, workforce, and #pricing models are being reimagined, read our insight on what this means for #healtheconomists: www.ohe.org/insight/heal...

Office of Health Economics @ohenews.bsky.social · Jun 12

There is a range of ways ex-US payers and pharma companies might respond to President Trump’s “Most Favoured Nation” drug pricing. Will any of them work to lower #US drug prices?

Read more: www.ohe.org/insight/the-trump-administrations-us-drug-pricing-proposal-what-will-happen-next/

1

Office of Health Economics @ohenews.bsky.social · Jun 11

New insight: 68% of OECD countries formally use #QALYs in pricing decisions, but practices vary. How consistent is economic evaluation across borders?
www.ohe.org/insight/how-...

#HTA #healtheconomics

2

Office of Health Economics @ohenews.bsky.social · Jun 10

New report on STRIDES—a framework to better value AMR #diagnostics. #Diagnostics are key to tackling #AMR, but #policy still overlooks their impact. Read more: www.ohe.org/publications...

1 3

Office of Health Economics @ohenews.bsky.social · Jun 9

Argentina plans a new national #HTA agency, ANEFiTS. A big step for evidence-based #policy, but key questions on governance, transparency & legal power remain. Read more: www.ohe.org/insight/arou...

2 1

Office of Health Economics @ohenews.bsky.social · Jun 5

New insight: a substantial proportion of these medicines do not deliver their intended therapeutic benefits for the individuals taking them, due to genetic variations.
##pharmacogenomics #CERSI

www.ohe.org/insight/pharmacogenomics-testing-a-crucial-piece-to-unlocking-the-full-value-of-medicines/

1

Office of Health Economics @ohenews.bsky.social · Jun 5

Vaccines return up to 19x their cost, but adult #immunisation is undervalued. Our new insight calls for long-term investment to boost health, productivity & system resilience. www.ohe.org/insight/prevention-pays-off-so-why-arent-we-doing-more-of-it/

1 1

Office of Health Economics @ohenews.bsky.social · Jun 2

President Trump says the rest of the world “free rides” on the #US – and wants to peg US #drugprices to other countries’. This isn’t a new idea – but what might be different with his latest Executive Order? Read more: www.ohe.org/insight/the-...

Office of Health Economics @ohenews.bsky.social · May 22

New OHE report: Europe is off-track to meet 2030 #HIV eradication targets. Rising diagnoses, late testing & mounting costs demand urgent action. We highlight key barriers, the cost of complacency & solutions. Read more: www.ohe.org/publications...

#publichealth #healtheconomics

1

Office of Health Economics @ohenews.bsky.social · May 20

How can the #UK prepare for an #ageingsociety? OHE’s submission to a #parliamentary inquiry stressed that keeping as many people as healthy and productive as possible – for as long as possible – is a requisite measure in addressing a shrinking #workforce. Read more: www.ohe.org/insight/offi...

1

Office of Health Economics @ohenews.bsky.social · May 19

Kenya is making progress on using evidence to guide healthcare decisions. New reforms embed #HTA in #policy, but challenges in capacity, funding and transparency remain. www.ohe.org/insight/arou...

1

Reposted by Office of Health Economics

Global Health Economics Centre @lshtm-gheco.bsky.social · May 14

Andy Briggs, presenting at #ISPORMontreal on whether we should be ‘greening’ our HTA methods in a panel organised by @ohenews.bsky.social on Environmental Sustainability and Whole Health. You can read the write up of his presentation on occamresearch.substack.com/p/greening-hta

1 1

Reposted by Office of Health Economics

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · May 12

"The Price Effects of Biosimilars In the US" by Mireia Jofre-Bonet et al. concludes the US biosimilars market has become highly competitive; driving price reductions between 2015-2023 with substantial savings for Medicare

➡️ tinyurl.com/PriceEffects...

@ohenews.bsky.social
#HealthEconomics

abstract of a new paper in Value in Health, May 2025, by Mireia Jofre-Bonet and colleagues about the effect of biosimilars on prices in the US

1 2

Office of Health Economics @ohenews.bsky.social · May 12

GLP-1s are changing #obesity care—but access, equity, and patient preferences raise new challenges. Our latest insight looks at what this means for #policy and practice. www.ohe.org/insight/glp-...

#healtheconomics #GLP1

1

Office of Health Economics @ohenews.bsky.social · May 8

📢 New publication from OHE: Understanding the full value of long-acting therapies: Less is more?

We will also be discussing this research at ISPOR 2025 in Issue Panel 116. Join us for the discussion!

Read it here: www.ohe.org/publications...

#healtheconomics #HTA

Understanding the Full Value of Long-Acting Therapies: less is more? - OHE

Long-acting therapies offer value for chronic disease, improving adherence and outcomes. This OHE report highlights HTA gaps, real-world evidence, and policy needs.

www.ohe.org

1